Ascendiant Capital Starts Apricus Biosciences (APRI) at Strong Buy; Major Inflection Point
Tweet Send to a FriendGet Alerts APRI Hot Sheet
Price: $2.57 -3.38%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade APRI Now!
Ascendiant Capital initiates coverage on Apricus Biosciences (NASDAQ: APRI) with a Strong Buy. PT $6.00.
Analyst, George Santana, said, "We believe Apricus represents one of today’s more timely small-cap investments in biopharmaceuticals. Apricus has its blockbuster-potential erectile dysfunction drug approved in Canada, licensed by Abbott (NYSE: ABT), and expected to commence sales by year-end. Other drugs in development are showing promise and earning licensing deals. In addition, Apricus is assembling a portfolio of already-approved and previously selling oncology support drugs; these are being prepped for re-launch and should begin contributing revenue prior to year-end."
"We believe Apricus will generate significant acquisition interest. Even so, management is building a company that is sustainable on its own."
For an analyst ratings summary and ratings history on Apricus Biosciences click here. For more ratings news on Apricus Biosciences click here.
Shares of Apricus Biosciences closed at $3.12 yesterday, with a 52 week range of $2.25-$5.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, George Santana, said, "We believe Apricus represents one of today’s more timely small-cap investments in biopharmaceuticals. Apricus has its blockbuster-potential erectile dysfunction drug approved in Canada, licensed by Abbott (NYSE: ABT), and expected to commence sales by year-end. Other drugs in development are showing promise and earning licensing deals. In addition, Apricus is assembling a portfolio of already-approved and previously selling oncology support drugs; these are being prepped for re-launch and should begin contributing revenue prior to year-end."
"We believe Apricus will generate significant acquisition interest. Even so, management is building a company that is sustainable on its own."
For an analyst ratings summary and ratings history on Apricus Biosciences click here. For more ratings news on Apricus Biosciences click here.
Shares of Apricus Biosciences closed at $3.12 yesterday, with a 52 week range of $2.25-$5.94.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Starts Insmed (INSM) at Buy
- Wells Fargo Starts StealthGas (GASS) at Outperform
- Baird Starts Quintiles (Q) at Neutral
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
